Alyssum Therapeutics key facts
as of Oct 2026- Developer of supramolecular therapeutics designed for cancer patients.
- Alyssum Therapeutics is valued at approximately $13.3M as of Oct 2026 (last reported valuation).
- It has raised $32.7M; the latest was Later Stage VC ($28.0M) in Jan 2025.
- Notable investors include Accel, REMUS Capital, FemHealth Ventures, Romulus Capital, Aarin Capital — 10 tracked in total.
- Status: Privately Held (backing).
Alyssum Therapeutics's last reported valuation, Mar 2017. Nothing priced has surfaced since.
- ·Watch Alyssum Therapeutics: the Monday email on marks, rounds and moves
Alyssum Therapeutics funding rounds
No funding rounds for Alyssum Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Alyssum Therapeutics valuation
Alyssum Therapeutics's last reported valuation was $13.3 million in Mar 2017. No priced round, secondary trade or fund mark has surfaced since.
Alyssum Therapeutics investors
10 investors are on record for Alyssum Therapeutics, including Accel, REMUS Capital, FemHealth Ventures and Romulus Capital.
About Alyssum Therapeutics
Developer of supramolecular therapeutics designed for cancer patients. The company offers treatments and antibody drugs to treat lung, testicular, colorectal, and childhood cancers, its therapeutics use supra-molecular technology to design anti-cancer drugs that home in on the tumor and modulate the tumor immune response, enabling oncologists to outsmart cancer cells in patients by activating the immune system.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2011
- Employees
- 4
- Website
- alyssumtx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.